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Objective: Several case reports have linked solvent exposure to Parkinson disease (PD), but few studies have
assessed associations with specific agents using an analytic epidemiologic design. We tested the hypothesis that
exposure to specific solvents is associated with PD risk using a discordant twin pair design.
Methods: Ninety-nine twin pairs discordant for PD ascertained from the National Academy of Sciences/National
Research Council World War II Veteran Twins Cohort were interviewed regarding lifetime occupations and hobbies
using detailed job task–specific questionnaires. Exposures to 6 specific solvents selected a priori were estimated by
expert raters unaware of case status.
Results: Ever exposure to trichloroethylene (TCE) was associated with significantly increased risk of PD (odds ratio
[OR], 6.1; 95% confidence interval [CI] 1.2–33; p ¼ 0.034), and exposure to perchloroethylene (PERC) and carbon
tetrachloride (CCl4) tended toward significance (respectively: OR, 10.5; 95% CI, 0.97–113; p ¼ 0.053; OR, 2.3; 95%
CI, 0.9–6.1; p ¼ 0.088). Results were similar for estimates of exposure duration and cumulative lifetime exposure.
Interpretation: Exposure to specific solvents may increase risk of PD. TCE is the most common organic contaminant
in groundwater, and PERC and CCl4 are also ubiquitous in the environment. Our findings require replication in other
populations with well-characterized exposures, but the potential public health implications are substantial.
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Solvents are present in a wide range of products, suchas fuels, paints, glues, lubricants, degreasers, and
cleaning products. They have long been suspected as
potential causative agents in typical Parkinson disease
(PD), in part because of anecdotal reports of parkinson-
ism occurring in individuals with large exposures.1–5
Recently, Gash and colleagues reported a cluster of 3
individuals with PD who had extensive exposures to the
solvent trichloroethylene (TCE) in a small manufacturing
plant.6 Several other cases possibly related to TCE have
also been reported,7,8 but there are no analytic epidemio-
logic studies investigating a possible association with PD.
TCE is the most frequently reported organic contami-
nant in groundwater.9,10 If solvents such as TCE are
associated with PD risk, the public health implications
could be substantial.
For these reasons, we conducted a case–control study
to determine whether there are associations with specific
solvents that have been anecdotally associated with PD,
including TCE, tetrachloroethylene (also known as per-
chloroethylene [PERC]), carbon tetrachloride (CCl4), tolu-
ene, xylene, and n-hexane. We utilized a population of
twins discordant for PD with well-characterized exposure
to solvents and other environmental factors. Because twins
are genetically very similar or identical, and share many
demographic and lifestyle factors, discordant twin-pair
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designs are more resistant to confounding factors than typ-
ical case–control study designs.11
Subjects and Methods
Case Ascertainment
Study subjects were members of the National Academy of Sci-
ences/National Research Council World War II Veteran Twins
Registry, an all-male twin cohort established in the 1960s using
military records.12 Detailed methods have been previously pub-
lished.13 Briefly, from 1993 to 1995, we attempted to contact all
19,842 individual twins believed to be alive and administered a
brief telephone interview screening for symptoms of parkinson-
ism.14 Cases from the Twin Registry were also ascertained
through searches of medical databases of the Department of Vet-
eran Affairs, the Health Care Financing Administration, and the
National Death Index, by referral from an ongoing study of
dementia in the registry,15 and through a second cohort-wide
screen conducted 5 years later. Twins with suspected parkinson-
ism and their twin brothers received an in-person evaluation by a
movement disorders specialist that included a neurological exam
and scripted videotaping of the exam. Medical records were also
obtained. Diagnosis was determined by consensus of 2 neurolo-
gists using all available information, applying standard criteria.16–18
We identified 220 individual twins with PD.
The study received institutional review board approval,
and all participants provided written informed consent.
Exposure Assessment
Lifetime exposures were inferred for 6 specific solvents that had
been previously linked to PD or parkinsonism in case reports or
analytic studies: n-hexane, xylene, toluene, CCl4, TCE, and
PERC. We utilized occupational exposure assessment methods
previously developed for cancer research.19–22 Fifty-two job task–
specific structured questionnaires were adapted from Stewart et
al23 or developed de novo to collect highly detailed task-, pro-
cess-, and material-specific information for a broad range of
occupations. These instruments could be administered consis-
tently by interviewers without specialized industrial hygiene train-
ing. Initial interviews collected occupational history overviews for
all jobs held >6 months from age 10 years onward, including
detailed information on years of employment, company name
and location, products made, job titles, and a description of the
tasks performed in each job. Hobby histories were also collected.
Historical overviews were reviewed to assign the appropriate job
task–specific structured questionnaires for subsequent interviews.
The industrial hygienist and/or occupational medicine
physician, unaware of case status, reviewed all available occupa-
tional information. Using extensive probability databases24
(E.A. Katz, unpublished data; J. Siemiatycki, unpublished data)
and multiple reference sources,19,23,25–29 solvent exposures were
inferred for each job in the context of the subject’s detailed
description of the job or hobby, industry, tasks, and time
period.19,21,27,30,31 Ever exposure to a solvent was defined as
exposure at least 2% of work time or 1 hour per week. Expo-
sure intensity was coded for each job or hobby as low, medium,
or high, corresponding to 2.5 parts per million (ppm), 25ppm,
and 100ppm respectively.32,33 A cumulative exposure index
(CEI) was calculated for each solvent as the product of expo-
sure intensity, hours exposed per year, and years exposed, sum-
ming across all jobs and hobbies. A combined variable for expo-
sure to either TCE or PERC was also considered, because these
compounds are thought to share toxic properties.34–36
Additional questionnaires collected data on lifetime his-
tory of smoking and head injury. Smoking was defined as
smoking at least 1 cigarette per day for 6 months or longer.37
Head injury was defined as ever having a head injury that
resulted in a loss of consciousness or amnesia.38 Trained inter-
viewers administered all risk factor questionnaires by telephone.
Suitable proxy informants were identified for deceased and cog-
nitively impaired subjects scoring <27 on the education-
adjusted Modified Telephone Interview for Cognitive Status.39
Statistical Analysis
Paired analyses were performed in monozygotic (MZ) and dizy-
gotic (DZ) twins discordant for PD. For all risk variables, observa-
tions for both twins were truncated at the PD diagnosis age in
the affected twin or the last year for which information was avail-
able (the index date), whichever was earlier. Continuous variables
were compared using Wilcoxon signed-rank tests. McNemar test
with exact p values was used for dichotomous variables. All
reported p values are 2-tailed. Exposure duration and CEI were
analyzed as tertiles based on their distribution in control twins.
For PERC exposure duration, tertiles were based on its distribu-
tion in all subjects, because few controls were exposed. Condi-
tional logistic regression to account for matching within twin pairs
was used to adjust for potential confounding by smoking and
respondent type (subject or proxy), and to calculate odds ratios
(ORs) and 95% confidence intervals (CIs) for each solvent.
Sensitivity analyses considered occupational exposures only
(ie, excluding hobby-related exposures), as well as models adjusted
for head injury and smoking pack-years, stratified by zygosity, and
lagged to exclude solvent exposures within 10 years of the index
date. Because matched-pair analyses exclude individuals for whom
paired data are incomplete, a sensitivity analysis also measured sol-
vent associations with PD in unpaired models. Analyses were con-
ducted with SPSS version 12.0 (http://spss.com).
Results
A total of 198 PD-discordant pairs were identified (85
MZ, 110 DZ, 3 unknown zygosity). Occupational histor-
ies were completed by 126 (63.6%) individual twins with
PD, 119 (60.1%) individual twins without PD, and by
both twins in 99 pairs (49 MZ, 50 DZ; Table 1). Among
these, interviews were completed with proxy informants
for 46.5% of twins with PD and 18.2% of control twins.
Most proxy informants were spouses (58%), twin brothers
(22%), or other siblings (13%). Age at PD diagnosis and
age at interview of twins who completed the interview
were similar to those of noncompleting twins.
Goldman et al: Solvents and PD
June 2012 777
Frequencies of ever being exposed to each solvent
and the most commonly associated job or hobby types
are shown in Table 2. Associations with job categories
tended toward significance only for industrial machinery
repairer (OR, 3.0; 95% CI, 0.8–11.2), and industrial
worker (OR, 2.3; 95% CI, 0.9–5.9). Exposure frequen-
cies in twin pairs (ie, either twin was exposed) ranged
from 6% for PERC to 27% for toluene, and in 48% of
pairs at least 1 twin was exposed to 1 or more of the 6
solvents studied. ORs for ever being exposed were greater
than unity for every solvent (Table 3). The adjusted OR
was significantly increased for TCE (OR, 6.1; 95% CI,
1.2–33; p ¼ 0.034) and tended toward significance for
PERC (OR, 10.5; 95% CI, 0.97–113; p ¼ 0.053) and
CCl4 (OR, 2.3; 95% CI, 0.9–6.1, 0.088). Risk was also
significantly increased for the combined variable TCE or
PERC exposure (OR, 8.9; 95% CI, 1.7–47; p ¼ 0.01).
Risk was modestly, although nonsignificantly, increased
for exposure to any of the 6 solvents, or any of 4 solvents
excluding PERC and TCE. Risk associated with TCE or
PERC exposure was only minimally attenuated when a
variable for exposure to any of the other 4 solvents
was included in the model (OR, 8.3; 95% CI, 1.6–44;
p ¼ 0.013). Mean time from first exposure until index
date ranged from 25 years for n-hexane to 41 years for
xylene (Table 4). Solvent exposure was not significantly
associated with PD diagnosis age, but we had limited
power to assess this relationship.
Associations with exposure duration and CEI were
similar to those for ever exposure, with significantly
increased risk for TCE and near significance for PERC
(see Table 4). For every solvent, exposure estimates were
lower for proxy-provided than for subject-provided occu-
pational histories in both case and control subjects.
Although precision was reduced, results were similar
when pairs with a proxy respondent were excluded from
analyses (TCE: OR, 6.0; 95% CI, 0.7–50; TCE or
PERC: OR, 7.0; 95% CI, 0.9–57). Results were also
similar in models that excluded hobby-related exposures
or that included head injury or smoking pack-years, or
were stratified by zygosity (data not shown), as well as in
unmatched analyses (Table 5).
Discussion
To the best of our knowledge, this is the first confirma-
tion of a significant association between TCE exposure
TABLE 1: PD-Discordant Twin Subject Characteristics
Characteristic Value
Age at PD diagnosis, mean (SD), range
Individual twins with PD who completed interview, n ¼ 126 66.2 (8.7), 35–84
Both members of twin pair completed interview, n ¼ 99 65.4 (8.3), 39–83
Individual twins with PD who did not complete interview, n ¼ 72 68.8 (9.5), 25–87
PD duration at time of interview, mean (SD), range
Individual twins with PD who completed interview 7.6 (6.8), 0–34
Both members of twin pair completed interview 8.0 (6.5), 0–30
Individual twins with PD who did not complete interview 7.1 (7.9), 0–50
Zygosity
Completing pairs, n ¼ 99 49 MZ; 50 DZ
Noncompleting pairs, n ¼ 99 36 MZ; 60 DZ; 3 unknown
Characteristics in Pairs Completing
Interview, n ¼ 99 pairs
PD-Affected
Twin
PD-Unaffected
Twin
P
Proxy respondent proportion 46% 18% <0.001
Ever regular cigarette smoking 54% 62% 0.3
Pack-years cigarette smoking, mean (SD) 16 (23) 24 (31) 0.024
Ever head injury 24% 9% 0.015
DZ ¼ dizygotic; MZ ¼ monozygotic; PD ¼ Parkinson disease; SD ¼ standard deviation.
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and PD risk in a population-based study. Two other
chlorinated solvents, PERC and CCl4, tended toward sig-
nificantly increased risk. Results were similar in analyses
considering ever/never exposure, exposure duration, or
lifetime cumulative exposure. Our findings are consistent
with prior case reports6–8 and a rodent model of TCE-
induced parkinsonism that recapitulates key pathological
and neurochemical features of PD.40 In this model, TCE
caused selective dose-dependent loss of dopaminergic
neurons in the substantia nigra pars compacta (SNpc),
and selective accumulation of a-synuclein protein in the
dorsal motor nucleus of the vagus nerve and SNpc, a
TABLE 2: Solvent Exposure Frequencies in PD-Discordant Twin Pairs, n 5 99 Pairs
Solvent Case
Exposure
Frequency
Control
Exposure
Frequency
Proportion of
Pairs With Either
Twin Exposed
Most Frequent
Job or Hobby Types With Exposure
(in order of frequency)
Toluene 18% 16% 27% Cabinet maker, artist, mechanic,
electrician, carpenter
Xylene 9% 5% 11% Artist, laboratory technician,
groundskeeper, cabinet maker
n-Hexane 7% 8% 14% Cabinet maker, carpenter,
mechanic, shoemaker
CCl4 16% 11% 25% Electrician, mechanic, aircraft mechanic,
painter, dry cleaner, industrial worker
PERC 5% 1% 6% Electrician, dry cleaner, artist
TCE 10% 3% 12% Electrician, dry cleaner, industrial
machinery repairer, health worker
TCE or PERC 12% 3% 14% n/a
Any of 6 solvents 34% 29% 48% n/a
CCl4 ¼ carbon tetrachloride; n/a ¼ not applicable; PD ¼ Parkinson disease; PERC ¼ perchloroethylene (tetrachloroethylene);
TCE ¼ trichloroethylene.
TABLE 3: Solvent Exposure Frequencies and Adjusted Pairwise Odds Ratios in PD–Discordant Twins, n 5 99
Pairsa
Solvent Case/
Control
Caseþ/
Control
Case/
Controlþ
Caseþ/
Controlþ
Ever/Never
Exposed,
OR (95% CI)
p
Toluene 72 11 9 7 1.3 (0.5–3.3) >0.2
Xylene 88 6 2 3 2.2 (0.4–12) >0.2
n-Hexane 85 6 7 1 1.3 (0.4–4.1) >0.2
CCl4 74 14 9 2 2.3 (0.9–6.1) 0.088
PERC 93 5 1 0 10.5 (0.97–113) 0.053
TCE 87 9 2 1 6.1 (1.2–33) 0.034
TCE or PERC 85 11 2 1 8.9 (1.7–47) 0.010
Any of 6 solvents 51 19 14 15 1.7 (0.8–3.7) 0.16
Any of 4 excluding
TCE and PERC
53 18 15 13 1.5 (0.7–3.1) >0.2
aEver exposure, adjusted for respondent type and smoking.
CCl4 ¼ carbon tetrachloride; CI ¼ confidence interval; OR ¼ odds ratio; PD ¼ Parkinson disease; PERC ¼ perchloroethylene
(tetrachloroethylene); TCE ¼ trichloroethylene.
Goldman et al: Solvents and PD
June 2012 779
pattern consistent with human pathological staging of
PD.41 TCE also reduced mitochondrial complex 1 activ-
ity, similar to the neurotoxin 1-methyl-4-phenylpyridi-
nium (MPPþ), the insecticide rotenone, and the mito-
chondrial deficiency seen in typical PD.42,43 Like TCE,
PERC44,45 and CCl4
46–48 have also been shown to
increase markers of oxidative and nitrative stress, activate
microglia, and disrupt mitochondrial function.49–53
Because of their lipophilic nature, each of these com-
pounds readily distributes in body tissues and particularly
the brain.10,54,55
TCE, PERC, and CCl4 have been used extensively
worldwide for decades.10,56,57 TCE has been used as a
dry cleaning and degreasing agent, and as an additive in
many common household products, including typewriter
correction fluid, adhesives, paints, and carpet cleaners
and spot removers. In 1977, the US Food and Drug
Administration banned its use as a general anesthetic,
TABLE 4: Solvent Exposure Duration and Cumulative Exposure Index, n 5 99 Pairs
Solvent First Exposure
Preceding
Index Date,
Mean
yr (SD)
Job/Hobby
Duration
in Exposed
PD Twins,
Mean
yr (SD)
Job/Hobby
Duration
in Exposed
Control
Twins, Mean
yr (SD)
Durationa
OR [95%
CI]
Duration
p
CEIa OR
[95% CI]
CEI p
Toluene 38.4 (16.6) 28.0 (22.4) 15.8 (15.3) 1.3 [0.7–2.6] >0.2 1.4 [0.6–3.0] >0.2
Xylene 41.4 (15.8) 38.6 (21.9) 17.0 (14.5) 2.5 [0.7–9.1] 0.15 1.8 [0.6–5.2] >0.2
n-Hexane 24.8 (15.5) 8.7 (10.8) 11.1 (14.1) 1.0 >0.2 1.5 [0.6–3.9] >0.2
CCl4 39.7 (14.7) 13.2 (17.6) 7.6 (10.7) 1.9 [0.8–9.0] 0.14 1.7 [0.8–3.8] 0.18
PERC 33.3 (13.2) 25.8 (19.7) 13 (n/a) 3.4 [0.9–12] 0.07 9.3 [0.8–100] 0.07
TCE 38.3 (11.4) 18.6 (18.0) 9.0 (4.0) 3.2 [1.1–10] 0.03 5.2 [1.03–26] 0.046
TCE or
PERCb
38.3 (10.5) 18.5 (17.8) 9.0 (4.0) 4.1 [1.4–11.8] 0.009 7.2 [1.4–37] 0.018
aRisk associated with a 1-tertile difference, adjusted for respondent type and smoking.
bLongest of either TCE or PERC exposure.
CCl4 ¼ carbon tetrachloride; CEI ¼ cumulative exposure index; CI ¼ confidence interval; OR ¼ odds ratio; PERC ¼ perchloro-
ethylene (tetrachloroethylene); SD ¼ standard deviation; TCE ¼ trichloroethylene.
TABLE 5: Solvent Exposure Frequencies and Risk in Unpaired Analyses
Solvent Case %
Exposed,
n ¼ 126
Control %
Exposed,
n ¼ 119
Ever/Never
OR (95%
CI)a
Ever/
Never
p
Durationa,b
OR (95%
CI)
Duration
p
CEIa,b OR
(95% CI)
CEI p
Xylene 7.9% 5.9% 1.5 (0.5–4.2) >0.2 1.5 (0.8–3.0) 0.25 1.4 (0.5–3.8) >0.2
Toluene 15.9% 16.0% 1.2 (0.6–2.4) >0.2 1.4 (0.8–2.4) >0.2 1.0 (0.4–2.2) >0.2
n-Hexane 5.6% 9.2% 0.8 (0.3–2.2) >0.2 0.7 (0.3–1.9) >0.2 0.4 (0.14–1.3) 0.13
CCl4 16.7% 10.9% 2.2 (1.0–4.9) 0.043 1.8 (0.95–3.5) 0.07 2.2 (0.85–5.8) 0.11
PERC 4.0% 0.8% 6.5 (0.7–58) 0.096 4.9 (0.7–35) 0.12 5.4 (0.7–44) 0.11
TCE 7.9% 2.5% 3.3 (0.97–11) 0.056 3.1 (1.0–9.7) 0.05 3.1 (1.03–9.1) 0.043
TCE or
PERC
9.5% 2.5% 3.8 (1.2–13) 0.027 3.6 (1.2–10.3) 0.018 3.7 (1.2–11) 0.02
aAdjusted for respondent type, smoking, index age.
bRisk associated with a 1-tertile difference.
CCl4 ¼ carbon tetrachloride; CEI ¼ cumulative exposure index; CI ¼ confidence interval; OR ¼ odds ratio; PERC ¼ perchloro-
ethylene (tetrachloroethylene); TCE ¼ trichloroethylene.
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skin disinfectant, grain fumigant, and coffee decaffeinating
agent.10 Today, it is primarily used as a degreasing agent
in metal parts fabrication. Millions of pounds of TCE are
still released annually into the environment in the United
States. It is detected in air, soil, food, and human breast
milk, and is the most frequently reported organic contami-
nant in groundwater, found in up to 30% of US drinking
water supplies.10,54,55
Uses of PERC are similar to those of TCE.56
PERC has been the leading dry cleaning solvent since the
1950s.58 It is also used in textiles manufacturing and as a
degreasing agent, and is found in many common house-
hold products. PERC persists in air and groundwater for
several months or longer and is ubiquitous in human tis-
sues. CCl4 was the first chlorinated solvent used in dry
cleaning, predominating from 1930 until the early 1950s.
The major use of CCl4 has historically been for the pro-
duction of chlorofluorocarbons for use as refrigerants. CCl4
has also been used as an anesthetic and anti-helminth, and
in common household products. Until recently, it was used
as a fumigant to kill insects in grain. Because of its toxicity,
consumer and fumigant uses were phased out by 2000, but
industrial uses remain. CCl4 is a stable chemical that is
degraded very slowly, so it has gradually accumulated in the
environment, mainly the atmosphere.57
TCE and PERC are primarily metabolized by
CYP2E1 and glutathione transferase.35,45 A proposed proxi-
mate toxic species is 1-trichloromethyl-1,2,3,4-tetrahydro-
b-carboline, a potent mitochondrial complex 1 inhibitor,
dopaminergic toxin, and structural analogue of MPPþ that
forms in the presence of tryptamine after CYP2E1-medi-
ated oxidation (Fig).34,59,60 Consistent with this hypothesis,
pooled exposure to either TCE or PERC was associated
with markedly increased PD risk in our study.
Although odds ratios were greater than unity for
the other solvents studied, their magnitude of association
with PD was modest, and none approached significance.
Similarly, risk associated with exposure to any solvent or
with job categories was modest and nonsignificant. This
is consistent with the modest associations reported by 2
prior mortality studies,61,62 and the lack of association
reported by others,63–65 when broadly defined occupa-
tional solvent exposure categories were used.
The term solvent encompasses a wide range of com-
pounds, whose only common characteristics are their
ability to dissolve other substances. Although most sol-
vents are oxidative stressors,66–68 there is little reason to
assume these disparate molecular compounds share a
common neuronal toxicity.69 Because most prior studies
of occupational solvents and PD explored exposures in a
nonspecific manner, relationships with any particular eti-
ologic agent may have been obscured.
This study has several strengths. Because twins
share both genes and environment, the discordant twin
pair design is more resistant to confounding by unrecog-
nized genetic and environmental factors than standard
case–control designs, reducing the likelihood of spurious
results.11 We used validated exposure assessment methods
to minimize reporting bias. The traditional method to
obtain retrospective exposure information is to directly
query subjects about use of specific compounds, but this
method is prone to recall bias—the predilection of case
subjects to report exposures due to heightened awareness or
concern—and workers are often unaware of the specific
chemicals they are exposed to.70–72 Another strategy
requires highly trained interviewers who can probe for spe-
cific exposures, an approach that can introduce bias and is
impractical when many industries and jobs are being stud-
ied. To address these problems, we developed and system-
atically administered detailed, structured, task-based occupa-
tional questionnaires. Participants were unaware of study
hypotheses, and exposure inference was based on job tasks
rather than self-reported exposures, helping to reduce recall
bias. In addition, exposure classification bias was minimized
because expert raters were unaware of subject case status.
The major limitations of the study are its small sam-
ple size, which yielded imprecise risk estimates, and expo-
sure inferences based on retrospective recall—a virtually
FIGURE: TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-b-carboline) hypothesis.34 CYP2E1 5 cytochrome P-450 2E1; MPP1 5 1-
methyl-4-phenylpyridinium; PERC 5 perchloroethylene (tetrachloroethylene); TCE 5 trichloroethylene.
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unavoidable limitation for a disease such as PD, in which
relevant exposures may occur decades before clinical dis-
ease is apparent. Although our methods helped reduce
recall bias, exposure estimation without direct measure-
ment is imprecise. However, because raters were unaware
of case status, exposure misclassification would be toward
the null, reducing the likelihood of finding a significant
association. Another weakness is reliance on proxy inform-
ants for a large proportion of subjects, with a much
greater proportion among case subjects. However, assign-
ing exposures based on job tasks rather than relying exclu-
sively on self-reported chemical exposures should help
mitigate lack of knowledge on the part of the proxy. Fur-
thermore, because exposure estimates were lower for
proxy-provided histories than for subject-provided histor-
ies, bias would be expected to reduce rather than inflate
apparent disease associations. Finally, we adjusted for
respondent type in all logistic models, and results were
similar when proxy respondents were excluded from
analyses. Another limitation is the difficulty isolating
specific effects of single agents, because many work set-
tings involve exposure to multiple agents. Nonetheless,
our results were not uniform across solvents, suggesting
specific effects of individual agents, and associations
with TCE or PERC were only minimally attenuated
when a variable for exposure to other solvents was
included in logistic models.
Although the present work focused on occupational
exposures, solvents are ubiquitous in the environment,
and this is particularly true for those implicated in this
study—TCE, PERC, and CCl4. Our findings require
replication in other populations with well-characterized
exposures, but the potential public health implications
are considerable. One remarkable observation made in
all the reports linking TCE exposure with PD is the
very long time lag (10–40 years) between exposure and
clinical disease. These observations suggest that exposure
may trigger a degenerative cascade dependent on the
passage of time, providing a critical window of opportu-
nity to arrest the disease process before clinical symp-
toms are manifested.
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